Evidence map›Paper›PMID 35699772›Full record

ArticleNeuroradiology2022

Natural history of MRI brain volumes in patients with neuronal ceroid lipofuscinosis 3: a sensitive imaging biomarker.

Jan-Niklas Hochstein, A Schulz, M Nickel, S Lezius, M Grosser, J Fiehler, J Sedlacik, U Löbel

Open access · hybridAbstract read
In one paragraph

Article in Neuroradiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Reversible synaptic deficits in early-stage batten disease.Journal of translational medicine · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Brain proton MR spectroscopy measurements in CLN3 disease.Molecular genetics and metabolism · 2023
    Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Jan-Niklas HochsteinDepartment of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Lokstedter Weg 104, 20251, Hamburg, Germany. j.hochstein@ik-h.de.ORCID http://orcid.org/0000-0002-6699-9887
A SchulzDepartment of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
M NickelDepartment of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
S LeziusDepartment of Biometrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
M GrosserDepartment of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Lokstedter Weg 104, 20251, Hamburg, Germany.
J FiehlerDepartment of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Lokstedter Weg 104, 20251, Hamburg, Germany.
J SedlacikDepartment of Radiology, Great Ormond Street Hospital for Children, London, UK.
U LöbelDepartment of Radiology, Great Ormond Street Hospital for Children, London, UK.
Universität Hamburg · DEGreat Ormond Street Hospital · GB

Funding

Bundesministerium für Bildung und Forschung 01GM1516AEIT Health 66691 BATCureFP7 Ideas: European Research Council 281234
6 · The paper itself

Abstract

purposeGrey matter (GM) atrophy due to neuronal loss is a striking feature of patients with CLN3 disease. A precise and quantitative description of disease progression is needed in order to establish an evaluation tool for current and future experimental treatments. In order to develop a quantitative marker to measure brain volume outcome, we analysed the longitudinal volumetric development of GM, white matter (WM) and lateral ventricles and correlated those with the clinical course.

methodsOne hundred twenty-two MRI scans of 35 patients (21 females; 14 males; age 15.3 ± 4.8 years) with genetically confirmed CLN3 disease were performed. A three-dimensional T1-weighted sequence was acquired with whole brain coverage. Volumetric segmentation of the brain was performed with the FreeSurfer image analysis suite. The clinical severity was assessed by the Hamburg jNCL score, a disease-specific scoring system.

resultsThe volumes of supratentorial cortical GM and supratentorial WM, cerebellar GM, basal ganglia/thalamus and hippocampus significantly (r =  - 0.86 to - 0.69, p < 0.0001) decreased with age, while the lateral ventricle volume increased (r = 0.68, p < 0.0001). Supratentorial WM volume correlated poorer with age (r =  - 0.56, p = 0.0001). Supratentorial cortical GM volume showed the steepest (4.6% (± 0.2%)) and most uniform decrease with strongest correlation with age (r =  - 0.86, p < 0.0001). In addition, a strong correlation with disease specific clinical scoring existed for the supratentorial cortical GM volume (r = 0.85, p =  < 0.0001).

conclusionSupratentorial cortical GM volume is a sensitive parameter for assessment of disease progression even in early and late disease stages and represents a potential reliable outcome measure for evaluation of experimental therapies.

Indexed as

Neuronal Ceroid-LipofuscinosesAdolescentAtrophyBiomarkersBrainChildDisease ProgressionFemaleGray MatterHumansMagnetic Resonance ImagingMaleMembrane GlycoproteinsMolecular ChaperonesYoung AdultBiomarkersCLN3 protein, humanMembrane GlycoproteinsMolecular ChaperonesBrain volumetryCLN3 diseaseJNCLNatural disease courseNeuronal ceroid lipofuscinosis

Identifiers

PMID35699772
PMCPMC9474504
OpenAlexW4282837588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.